Aug 11 (Reuters) - Ionis Pharmaceuticals Inc
* Ionis to independently advance inotersen and IONIS-FB-L Rx
* Ionis Pharmaceuticals Inc - Has retained all rights to inotersen and IONIS-FB-L(Rx).
* Ionis Pharmaceuticals - As part of reprioritization of pipeline and strategic review of rare diseases business, GSK declined its options on both drugs
* Ionis Pharmaceuticals Inc - Plans to file for marketing authorization for inotersen this year to support a commercial launch of inotersen in 2018.
* Ionis Pharma- Plans to initiate first phase 2 study with IONIS-FB-L(Rx) in patients with dry amd later this year, studies in other indications in 2018 Source text for Eikon: Further company coverage: